Regeneron's $9.53 Billion Trading Volume Drops 36.42% Ranking 88th in Stock Market

On April 30, 2025, Regeneron's trading volume was $9.53 billion, down 36.42% from the previous day, ranking 88th in the day's stock market. Regeneron Pharmaceuticals (REGN) rose 5.25%.

Regeneron Pharmaceuticals, Inc. (REGN) has announced that it will be presenting at the 2025 Annual Meeting of Shareholders. The meeting will be held on May 15, 2025, at the company's headquarters in Tarrytown, New York. Shareholders of record as of March 15, 2025, are entitled to vote at the meeting. The company will discuss its financial performance, strategic initiatives, and future outlook during the meeting.

Regeneron Pharmaceuticals, Inc. (REGN) has reported that its EYLEA (aflibercept) injection has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of diabetic retinopathy. This approval is based on the results of two pivotal Phase 3 studies, which demonstrated the efficacy and safety of EYLEA in reducing the risk of vision loss in patients with diabetic retinopathy. The approval expands the indications for EYLEA, which is already approved for the treatment of wet age-related macular degeneration, macular edema following retinal vein occlusion, and diabetic macular edema.

Regeneron Pharmaceuticals, Inc. (REGN) has announced that it has entered into a collaboration with Sanofi to develop and commercialize a new class of bispecific antibodies for the treatment of cancer. The collaboration will focus on the development of bispecific antibodies that target multiple antigens on cancer cells, with the goal of enhancing the efficacy of cancer treatments. The companies will share the costs and profits of the collaboration, with Regeneron responsible for the development and manufacturing of the bispecific antibodies, and Sanofi responsible for the commercialization of the products.